Truist reiterates Hold on PTC Therapeutics stock after Q3 results
Truist Securities reiterated a Hold rating on PTC Therapeutics (PTCT) with a $62.00 price target after Q3 2026 results. The stock trades near its 52-week low. PTC reported $357.8M revenue, beating estimates, but a loss of $0.62 per share, missing expectations. Revenue growth was driven by SEPHIENCE and Evrysdi royalty income. Management expects SEPHIENCE to enter a mature growth phase. Truist sees challenges in expanding into the Kuvan-switcher market.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger a sell-off, but the revenue beat and product updates could limit downside.
Market read
First report of PTC Therapeutics' Q3 earnings, providing fresh data for traders.
What to watch
Potential upside from the Sephience product's mature growth phase and royalty income from Evrysdi.
Background
Truist Securities provided an analyst rating and price target following PTC Therapeutics' Q3 earnings release.
Ticker impact
Truist reiterated a Hold on PTC Therapeutics after its Q3 2026 earnings, reporting revenue $357.8M (beat) but a loss of $0.62 per share (miss).
downward pressure as investors price in the earnings shortfall
The EPS miss is a fresh negative catalyst; analysts maintain a Hold rating, suggesting limited upside.
Market effects
Biotech sector may see modest caution as earnings miss highlights profitability challenges.
U.S. biotech stocks could face slight pullback in early trading.
Limited to investors tracking U.S. biotech earnings.
Counterpoint
The revenue beat could support a short-term rally if investors focus on top-line growth.
Key entities
- companyPTC Therapeutics
Biotech firm reporting Q3 2026 results.
- analystTruist Securities
Issued Hold rating and $62 price target.
